Harsha Deshmukh Harsha Deshmukh Harsha Deshmukh has been appointed a member of the Board of Managing Directors with responsibility for…
New BPH module and clinical data reinforce the TULSA Procedure™’s versatility in prostate disease, superior patient benefits, and potential for…
Fireside chat scheduled for Tuesday, December 2, 2025 at 12:30 PM ETNEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- TG…
WINNIPEG, Manitoba, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announced…
SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel diseases,…
One-year anniversary of affiliation marked by national expansion in research and care for kids with complex conditionsMONTREAL and LONDON, Ontario,…
Daix (France), New York City (New York, United States), November 28, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”),…
Oslo, Norway, 28 November 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T Cell Receptor-based Natural Killer (TCR-NK)…
BEIJING, Nov. 27, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the…
If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the…